Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.53 |
| ▸ | ADCY5 | O95622 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 2/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751306 | 0.86 | PI4KA (0.50) | ADORA2AADORA1ADCY5ADORA2BEGFR | |
| SCHEMBL3520367 | 0.82 | ADORA2A (0.51) | ADORA2AADORA1ADCY5ADORA2BFGFR1 | |
| SCHEMBL13731483 | 0.81 | ADORA2A (0.56) | ADORA2AADORA1ALDH1A1ADORA2BPI4KA | |
| SCHEMBL3516432 | 0.79 | ADORA2A (0.56) | ADORA2AADORA1ADCY5ADORA2BPI4KA | |
| SCHEMBL3519511 | 0.79 | TGFBR1 (0.39) | FGFR1 | |
| SCHEMBL27889143 | 0.79 | BTK (0.52) | FGFR1 | |
| SCHEMBL3515942 | 0.79 | ADORA2A (0.56) | ADORA2AADORA1ADORA2B | |
| SCHEMBL20972819 | 0.78 | ADORA2A (0.53) | ADORA2AADORA1ADCY5ADORA2BFGFR1 | |
| SCHEMBL3520158 | 0.77 | ADORA2A (0.69) | ADORA2AADORA1ADCY5ADORA2BPI4KA | |
| SCHEMBL11909641 | 0.76 | ADORA2A (0.50) | ADORA2AADORA1ADCY5ALDH1A1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012148550-A1 | PRODRUGS OF THERAPEUTIC COMPOUNDS | MYREXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2219448-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | Myriad Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | ADORA2A 2396/4885ADORA1 2673/4885ADCY5 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.